

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

Listing of Claims:

1. (Currently Amended) A method for the identification of a human subject ~~subjects~~ having Alzheimer's disease responsive to treatment with a cholinomimetic drug, said method comprising determining the apoE allele load of said subject ~~presence of apoE4 gene alleles in said subject~~, wherein the absence of ~~an~~ *apoE4* gene allele in a biological sample of said subject identifies said subject as a subject whose Alzheimer's disease-related cognitive impairment is responsive to treatment with a cholinomimetic drug.

2. (Original) The method of claim 1, wherein said method further comprises administering to said subject having an absence of *apoE4* allele a therapeutically effective amount of a cholinomimetic drug.

3. (Original) The method of claim 2, wherein administration of the cholinomimetic drug improves cognitive performance.

4. (Currently Amended) A method for identifying a patient diagnosed with a cognitive impairment for participation ~~genotyping a patient sample with respect to apoE4 allele~~ in a clinical trial of a drug for the treatment of said cognitive impairment ~~impairments~~, said method comprising:

(a) identifying a patient as already diagnosed with said cognitive impairment ~~impairments~~, or as being predisposed to acquire or to be at risk for said cognitive impairment ~~impairments~~; and

(b) determining the apoE allele load of said patient ~~presence of apoE4 gene alleles in said patient~~, wherein absence of apoE4 gene allele indicates said patient is a desired candidate for participation in a clinical trial of a drug for the treatment of said cognitive impairment ~~the genotype of said patient sample with respect to apoE4 allele in a clinical trial of said drug allows the effects of said drug to be compared according to apoE4 genotype.~~

5. (Currently Amended) A method for identifying a patient diagnosed with Alzheimer's disease for participation ~~genotyping a patient sample with respect to apoE4 allele in a clinical trial of a drug for the treatment of Alzheimer's disease~~, said method comprising:

(a) identifying a patient as already diagnosed with said Alzheimer's disease or as being predisposed to acquire or to be at risk for said Alzheimer's disease; and

(b) determining the apoE allele load of said patient ~~presence of apoE4 gene alleles in said patient~~, wherein absence of apoE4 gene allele indicates said patient is a desired candidate for participation in a clinical trial of a drug for the treatment of Alzheimer's disease ~~the genotype of said patient sample with respect to apoE4 allele in said clinical trial of a drug for the treatment of said Alzheimer's disease allows the effects of said drug to be compared according to apoE4 genotype.~~

6-7 (Cancelled)

8. (Previously Presented) The method of claims 1, 2, 3, 4, or 5 wherein said drug is tacrine.

9. (New) The method of claims 1, 4, or 5 wherein determining the apoE allele load is by genotyping.

CONCLUSION


Applicant submits that the corrected Amendment to the Claims section presented above complies with the requirements of 37 C.F.R. § 1.121.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

June 24, 2004



Kristina Bieker-Brady, Ph.D., P.C.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045